HPV16 E7 (86-93)
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas.
For research use only. We do not sell to patients.
- CAS No.: 160212-93-1
- Formula: C37H66N8O10S
- Molecular Weight:815.03
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
HPV16 E7 (86-93) specific T cells are expandable upon IVS (in vitro stimulation) with cognate peptide-pulsed dendritic cells (DCs) and are reactive against peptide-pulsed targets or, in case of the E711-20 epitope-specific T cells, against HPV16 E7 expressing CaSki cell line[1].
For peptide HPV16 E7 (86-93), the only response against K562 cells pulsed with the corresponding peptide was significantly blocked by anti-HLA class I Ab w6/32, which was not the case for HPV16 E7 expressing tumor cell line CaSki. Precursor T cells specific for HPV16 E7 (86-93) peptide is able to differentiate, at least in vitro, into HPVspecific effector cells[1].
HPV16 E7 peptide-loaded autologous dendritic cells (DCs) are able to stimulate a specific cytotoxic CD8+ T-cell response[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 160212-93-1
-
Molecular Weight 815.03
-
Formula C37H66N8O10S
-
Sequence
Thr-Leu-Gly-Ile-Val-Cys-Pro-Ile
-
Sequence Shortening
TLGIVCPI
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115(1):136-49. [Content Brief]
[2]. Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118(8):1984-91. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)